BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klink M, Rahman MA, Song C, Dhanyamraju PK, Ehudin M, Ding Y, Steffens S, Bhadauria P, Iyer S, Aliaga C, Desai D, Huang S, Claxton D, Sharma A, Gowda C. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. Cancers (Basel) 2021;13:1127. [PMID: 33807974 DOI: 10.3390/cancers13051127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Nipun VB, Amin KA. Recent Advances in Protein Kinase CK2, a Potential Therapeutic Target in Cancer. Russ J Bioorg Chem. [DOI: 10.1134/s1068162022050144] [Reference Citation Analysis]
2 Yadav AK, Jang B. Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2. IJMS 2022;23:7274. [DOI: 10.3390/ijms23137274] [Reference Citation Analysis]
3 Schwarz R, Richter A, Ito ERD, Murua Escobar H, Junghanß C, Hinz B. Validation of an LC-MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma. Molecules 2022;27:2394. [PMID: 35458589 DOI: 10.3390/molecules27082394] [Reference Citation Analysis]
4 Rosales M, Rodríguez-ulloa A, Pérez GV, Besada V, Soto T, Ramos Y, González LJ, Zettl K, Wiśniewski JR, Yang K, Perera Y, Perea SE. CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition. Front Mol Biosci 2022;9:834814. [DOI: 10.3389/fmolb.2022.834814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rosales M, Pérez GV, Ramón AC, Cruz Y, Rodríguez-Ulloa A, Besada V, Ramos Y, Vázquez-Blomquist D, Caballero E, Aguilar D, González LJ, Zettl K, Wiśniewski JR, Yang K, Perera Y, Perea SE. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines 2021;9:766. [PMID: 34356831 DOI: 10.3390/biomedicines9070766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
6 Rosales M, Pérez GV, Ramón AC, Cruz Y, Rodríguez-ulloa A, Besada V, Ramos Y, Vázquez-blomquist D, Caballero E, Aguilar D, González LJ, Zettl K, Wiśniewski JR, Ke Y, Perera Y, Perea SE. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.. [DOI: 10.1101/2021.05.19.444866] [Reference Citation Analysis]